Novogen CEO Outlines Immediate Plans for Co

Loading...
Loading...
Novogen Limited
NVGN
today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the Company delivers the best value for shareholders. Acting Chief Executive Officer, Iain Ross, said the Company currently had an extensive program of activities underway including the lead pre-clinical programs, discovery programs and academic partnerships and initiatives, and he was working with the newly evolved Board and incumbent Scientific Management Team to review the Company's immediate priorities with the intent of providing a shareholder update by 1 September 2015. "We remain committed to exploiting and creating value from all our technology platforms in order to build a sustainable, international, biotech company. Whilst we do not rule out securing third party collaborations and partnerships to further validate and fund our programs, I can confirm there are no M&A plans," Mr Ross said. "Notwithstanding, it is clear that we cannot realistically undertake and fully resource all our research and development programs in parallel all the way through to market approval and launch. These are new ground-breaking
See full press release
Posted In: NewsGuidanceManagementPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...